Biomarkers of response and resistance to antiangiogenic therapy

Sorafenib in advanced hepatocellular carcinoma

Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097 · see citing works

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · see citing works

Tumor angiogenesis: therapeutic implications

Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187 · see citing works

Angiogenesis in cancer and other diseases

Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070 · see citing works

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761 · see citing works

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S. M., Négrier, S., Szczylik, C. A., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,752 · see citing works

Sorafenib in Advanced Hepatocellular Carcinoma

정, 재. (2008) · Cited by 5,606 · see citing works

Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy

Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · see citing works

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

Escudier, B. J., Eisen, T. G., Stadler, W. M., Szczylik, C. A., Oudard, S. M., Siebels, M., Négrier, S., Chevreau, C., Solska, E., Desai, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa060655 · Cited by 4,802 · see citing works

<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622 · see citing works

Angiogenesis in life, disease and medicine

Carmeliet, P. (2005) · Nature · doi:10.1038/nature04478 · Cited by 3,494 · see citing works

Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

Miller, K. D., Wang, M., Gralow, J. R., Dickler, M. N., Cobleigh, M., Perez, E. A., Shenkier, T. N., Cella, D. F., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,077 · see citing works

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

Demetri, G. D., van Oosterom, A. T., Garrett, C. R., Blackstein, M. E., Shah, M. H., Verweij, J., McArthur, G. A., Judson, I. R., Heinrich, M. C., Morgan, J. A., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69446-4 · Cited by 2,646 · see citing works

Transplacental Carcinogenesis by Stilbestrol

Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640 · see citing works

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · see citing works

Trastuzumab — Mechanism of Action and Use in Clinical Practice

Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,592 · see citing works

Molecular regulation of vessel maturation

Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,515 · see citing works

Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis

Pàez‐Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,344 · see citing works

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279 · see citing works

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)

McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162 · see citing works

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966 · see citing works

Tumor Angiogenesis

Kerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,962 · see citing works

AZD2171, a Pan-VEGF Receptor Tyrosine Kinase Inhibitor, Normalizes Tumor Vasculature and Alleviates Edema in Glioblastoma Patients

Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Zhang, W.-T., Duda, D. G., Cohen, K. S., Kozak, K. R., Cahill, D. P., Chen, P.-J., Zhu, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2006.11.021 · Cited by 1,769 · see citing works

Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

Ebos, J. M. L., Lee, C. R., Cruz‐Muñoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,710 · see citing works

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Motzer, R. J., Michaelson, M. D., Redman, B. G., Hudes, G. R., Wilding, G., Figlin, R. A., Ginsberg, M. S., Kim, S. T., Baum, C. M., DePrimo, S. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.2574 · Cited by 1,630 · see citing works

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621 · see citing works

Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy

Dvorak, H. F. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.088 · Cited by 1,574 · see citing works

Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation

Winkler, F., Kozin, S. V., Tong, R. T., Chae, S.-S., Booth, M. F., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., di Tomaso, E., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.011 · Cited by 1,170 · see citing works

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

Jain, R. K., Duda, D. G., Clark, J. W., & Loeffler, J. S. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0403 · Cited by 1,039 · see citing works

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

Rini, B. I., Halabi, S., Rosenberg, J. E., Stadler, W. M., Vaena, D. A., Ou, S., Archer, L. E., Atkins, J. N., Picus, J., Czaykowski, P. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9847 · Cited by 894 · see citing works

Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells

Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849 · see citing works

Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.

Relf, M., LeJeune, S., Scott, P. A. E., Fox, S. B., Smith, K. A., Leek, R., Moghaddam, A., Whitehouse, R. M., Bicknell, R., & Harris, A. L. (1997) · PubMed · Cited by 833 · see citing works

Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels

Fischer, C., Jonckx, B., Mazzone, M., Zacchigna, S., Loges, S., Pattarini, L., Chorianopoulos, E., Liesenborghs, L., Koch, M., Mol, M. D., et al. (2007) · Cell · doi:10.1016/j.cell.2007.08.038 · Cited by 780 · see citing works

Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiationRole of oxygenation, angiopoietin-1, and matrix metalloproteinases

WINKLER, F., Kozin, S. V., Tong, R. T., Chae, S.-K., Booth, M., Garkavtsev, I., Xu, L., Hicklin, D. J., Fukumura, D., & DiTomaso, E. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00305-8 · Cited by 685 · see citing works

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

Schneider, B. P., Wang, Μ., Radovich, M., Sledge, G. W., Badve, S., Thor, A. D., Flockhart, D. A., Hancock, B. A., Davidson, N. E., Gralow, J. R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1612 · Cited by 604 · see citing works

Vascular normalization in Rgs5-deficient tumours promotes immune destruction

Hamzah, J., Jugold, M., Kiessling, F. M., Rigby, P. J., Manzur, M., Marti, H. H., Rabie, T., Kaden, S., Gröne, H., Hämmerling, G. J., et al. (2008) · Nature · doi:10.1038/nature06868 · Cited by 565 · see citing works

REporting recommendations for tumor MARKer prognostic studies (REMARK)

McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0252 · Cited by 562 · see citing works

Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II Study

Willett, C. G., Duda, D. G., di Tomaso, E., Boucher, Y., Ancukiewicz, M., Sahani, D. V., Lahdenranta, J., Chung, D. C., Fischman, A. J., Lauwers, G. Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1771 · Cited by 509 · see citing works

Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study

Zhu, A. X., Sahani, D. V., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Catalano, O. A., Sindhwani, V., Blaszkowsky, L. S., Yoon, S. S., Lahdenranta, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.9908 · Cited by 477 · see citing works

Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer Patients

Willett, C. G., Boucher, Y., Duda, D. G., di Tomaso, E., Munn, L. L., Tong, R. T., Kozin, S. V., Petit, L., Jain, R. K., Chung, D. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.5635 · Cited by 420 · see citing works

Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide With Bevacizumab and Pegylated Interferon Alfa-2b

Yao, J. C., Phan, A. T., Hoff, P. M., Chen, H. X., Charnsangavej, C., Yeung, S. J., Hess, K. R., Ng, C. S., Abbruzzese, J. L., & Ajani, J. A. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.6374 · Cited by 415 · see citing works

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

Sorensen, A. G., Batchelor, T. T., Zhang, W., Chen, P.-J., Yeo, P., Wang, M., Jennings, D. L., Wen, P. Y., Lahdenranta, J., Ancukiewicz, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0814 · Cited by 395 · see citing works

Silencing or Fueling Metastasis with VEGF Inhibitors: Antiangiogenesis Revisited

Loges, S., Mazzone, M., Hohensinner, P. J., & Carmeliet, P. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.02.007 · Cited by 393 · see citing works

Antitumor Activity and Biomarker Analysis of Sunitinib in Patients With Bevacizumab-Refractory Metastatic Renal Cell Carcinoma

Rini, B. I., Michaelson, M. D., Rosenberg, J. E., Bukowski, R. M., Sosman, J. A., Stadler, W. M., Hutson, T. E., Margolin, K. A., Harmon, C. S., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5416 · Cited by 393 · see citing works

Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study

Chen, W., Delaloye, S., Silverman, D. H. S., Geist, C. L., Czernin, J. G., Sayre, J. W., Satyamurthy, N., Pope, W. B., Lai, A., Phelps, M. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5825 · Cited by 391 · see citing works

Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer

Jubb, A. M., Hurwitz, H. I., Bai, W., Holmgren, E. B., Tobin, P., Guerrero, A., Kabbinavar, F. F., Holden, S. N., Novotny, W. F., Frantz, G. D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5388 · Cited by 385 · see citing works

Technology Insight: water diffusion MRI—a potential new biomarker of response to cancer therapy

Patterson, D. M., Padhani, A. R., & Collins, D. J. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1073 · Cited by 370 · see citing works

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

Ebos, J. M. L., Lee, C. R., Christensen, J. G., Mutsaers, A. J., & Kerbel, R. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708148104 · Cited by 368 · see citing works

Key factors in the acquisition of contrast kinetic data for oncology

Evelhoch, J. L. (1999) · Journal of Magnetic Resonance Imaging · doi:10.1002/(sici)1522-2586(199909)10:3 · Cited by 366 · see citing works

Prognostic versus predictive value of biomarkers in oncology

Oldenhuis, C. N. A. M., Oosting, S. F., Gietema, J. A., & de Vries, E. G. E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.03.006 · Cited by 349 · see citing works

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

DePrimo, S. E., Bello, C. L., Smeraglia, J., Baum, C. M., Spinella, D. G., Rini, B. I., Michaelson, M. D., & Motzer, R. J. (2007) · Journal of Translational Medicine · doi:10.1186/1479-5876-5-32 · Cited by 319 · see citing works

Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab

Ince, W. L., Jubb, A. M., Holden, S. N., Holmgren, E. B., Tobin, P., Sridhar, M., Hurwitz, H. I., Kabbinavar, F. F., Novotny, W. F., Hillan, K. J., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji174 · Cited by 318 · see citing works

Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor–Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice

Kamoun, W. S., Ley, C. D., Farrar, C. T., Duyverman, A. M., Lahdenranta, J., Lacorre, D. A., Batchelor, T. T., di Tomaso, E., Duda, D. G., Munn, L. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.9356 · Cited by 309 · see citing works

Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors

Drevs, J., Siegert, P., Medinger, M., Mross, K. B., Strecker, R., Zirrgiebel, U., Harder, J., Blum, H. E., Robertson, J. D., Jürgensmeier, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2066 · Cited by 303 · see citing works

Functional Diffusion Map As an Early Imaging Biomarker for High-Grade Glioma: Correlation With Conventional Radiologic Response and Overall Survival

Hamstra, D. A., Galbán, C. J., Meyer, C. R., Johnson, T. D., Sundgren, P. C., Tsien, C. I., Lawrence, T. S., Junck, L., Ross, D. J., Rehemtulla, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.2363 · Cited by 282 · see citing works

Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study

Dowlati, A., Gray, R. J., Sandler, A. B., Schiller, J. H., & Johnson, D. H. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1154 · Cited by 262 · see citing works

Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I Study

Liu, G., Rugo, H. S., Wilding, G., McShane, T. M., Evelhoch, J. L., Ng, C. S., Jackson, E. F., Kelcz, F., Yeh, B. M., Lee, F. T., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.143 · Cited by 260 · see citing works

Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PTK787/ZK 222584 Administered Twice Daily in Patients With Advanced Cancer

Thomas, A., Morgan, B., Horsfield, M. A., Higginson, A., Kay, A., Lee, L., Masson, E., Puccio-Pick, M., Laurent, D., & Steward, W. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.034 · Cited by 228 · see citing works

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma

Motzer, R. J., Bukowski, R. M., Figlin, R. A., Hutson, T. E., Michaelson, M. D., Kim, S. T., Baum, C. M., & Kattan, M. W. (2008) · Cancer · doi:10.1002/cncr.23776 · Cited by 212 · see citing works

Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells.

Yoshiji, H., Harris, S. R., & Thorgeirsson, U. P. (1997) · PubMed · Cited by 204 · see citing works

Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor

Norden-Zfoni, A., Desai, J., Manola, J. B., Beaudry, P., Force, J. M., Maki, R. G., Folkman, J., Bello, C. L., Baum, C. M., DePrimo, S. E., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0919 · Cited by 199 · see citing works

Response criteria for glioma

Sorensen, A. G., Batchelor, T. T., Wen, P. Y., Zhang, W., & Jain, R. K. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1204 · Cited by 191 · see citing works

Polymorphisms and Clinical Outcome in Recurrent Ovarian Cancer Treated with Cyclophosphamide and Bevacizumab

Schultheis, A. M., Lurje, G., Rhodes, K. E., Zhang, W., Yang, D., García, A. A., Morgan, R. J., Gandara, D. R., Scudder, S., Oza, A. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0351 · Cited by 182 · see citing works

Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer

Jain, R. K. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2346 · Cited by 167 · see citing works

Early Antiangiogenic Activity of Bevacizumab Evaluated by Computed Tomography Perfusion Scan in Patients with Advanced Hepatocellular Carcinoma

Zhu, A. X., Holalkere, N.-S., Muzikansky, A., Horgan, K. E., & Sahani, D. V. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0174 · Cited by 161 · see citing works

Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer

Crabb, S. J., Patsios, D., Sauerbrei, E. E., Ellis, P. M., Arnold, A., Goss, G. D., Leighl, N. B., Shepherd, F. A., Powers, J., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2545 · Cited by 159 · see citing works

Retrospective Evaluation of the Clinical and Radiographic Risk Factors Associated With Severe Pulmonary Hemorrhage in First-Line Advanced, Unresectable Non–Small-Cell Lung Cancer Treated With Carboplatin and Paclitaxel Plus Bevacizumab

Sandler, A. B., Schiller, J. H., Gray, R. J., Dimery, I. W., Brahmer, J. R., Samant, M. K., Wang, L. I., & Johnson, D. H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.2412 · Cited by 154 · see citing works

Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard Therapy

Saltz, L. B., Rosen, L. S., Marshall, J. L., Belt, R. J., Hurwitz, H. I., Eckhardt, S., Bergsland, E. K., Haller, D. G., Lockhart, A. C., Lima, C. M. R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.8637 · Cited by 141 · see citing works

VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy

Burstein, H. J., Chen, Y., Parker, L. M., Savoie, J., Younger, J., Kuter, I., Ryan, P. D., Garber, J. E., Chen, H., Campos, S. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0593 · Cited by 139 · see citing works

Magnetic Resonance Imaging–Measured Blood Flow Change after Antiangiogenic Therapy with PTK787/ZK 222584 Correlates with Clinical Outcome in Metastatic Renal Cell Carcinoma

de BAZELAIRE, C., Alsop, D. C., George, D. J., Pedrosa, I., Wang, Y., Michaelson, M. D., & Rofsky, N. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0417 · Cited by 113 · see citing works

Platelets Take Up the Monoclonal Antibody Bevacizumab

Verheul, H. M. W., Lolkema, M. P., Qian, D. Z., Hilkes, Y. H. A., Liapi, E. A., Akkerman, J. N., Пили, Р., & Voest, E. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0847 · Cited by 113 · see citing works

Association of diastolic blood pressure (dBP) ≥ 90 mmHg with overall survival (OS) in patients treated with axitinib (AG- 013736)

Rini, B. I., Schiller, J. H., Fruehauf, J. P., Cohen, E. E. W., Tarazi, J., Rosbrook, B., Ricart, A. D., Olszanski, A. J., Kim, S., & Spano, J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3543 · Cited by 93 · see citing works

Magnetic Resonance As a Cancer Imaging Biomarker

Sorensen, A. G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.6597 · Cited by 79 · see citing works

Drug Insight: intracellular inhibitors of HER2—clinical development of lapatinib in breast cancer

Cameron, D., & Stein, S. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1156 · Cited by 75 · see citing works

A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma

Mita, M. M., Rowinsky, E. K., Forero, L., Eckhart, S. G., Izbicka, E., Weiss, G. R., Beeram, M., Mita, A. C., Bono, J. S. D., Tolcher, A. W., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0255-0 · Cited by 48 · see citing works

Final results of CONFIRM 2: A multinational, randomized, double-blind, phase III study in 2nd line patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK787/ZK 222584 (PTK/ZK) or placebo

Köhne, C.-H., Bajetta, E., Lin, E. H., Valle, J. W., Cutsem, E. V., Hecht, J. R., Moore, M., Germond, C. J., Meinhardt, G., & Jacques, C. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.4033 · Cited by 47 · see citing works

Expensive Cancer Drugs With Modest Benefit Ignite Debate Over Solutions

Sinha, G. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn357 · Cited by 18 · see citing works

Novel risk-sharing scheme puts the spotlight on biomarkers

Hughes, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2478 · Cited by 16 · see citing works

A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis

Tannir, N. M., Zurita, A. J., Heymach, J. V., Tran, H., Pagliaro, L. C., Corn, P. G., Aparicio, A. M., Ashe, R., Wright, J. R., & Jonasch, E. W. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.5093 · Cited by 13 · see citing works

Abstract LB-247: A multidisciplinary phase II study of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma

Batchelor, T. T., Sorensen, A. G., di Tomaso, E., Duda, D. G., Zhang, W., Ancukiewicz, M., Lahdenranta, J., Louis, D. N., Plotkin, S. R., Ivy, P. S., et al. (2008) · Cancer Research · doi:10.1158/1538-7445.am2008-lb-247 · Cited by 12 · see citing works

Use of intratumoral mRNA expression of genes involved in angiogenesis and HIF1 pathway to predict outcome to VEGFR tyrosine kinase inhibitor (TKI) in patients enrolled in CONFIRM1 and CONFIRM2

Wilson, P. M., Yang, D., Shi, M., Zhang, W., Jacques, C. J., Barrett, J. C., Daneneberg, K., Trarbach, T., Folprecht, G., Meinhardt, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4002 · Cited by 10 · see citing works

Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC

Heymach, J. V., Hanrahan, E. O., Mann, H., Langmuir, P. B., Natale, R. B., Johnson, B. E., Herbst, R. S., & Ryan, A. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.8009 · Cited by 10 · see citing works

A comparative study of circulating endothelial cells (CECs) and circulating progenitor cells (CPCs) kinetics in four multidisciplinary phase II studies of antiangiogenic agents

Duda, D. G., Cohen, K. S., Ancukiewicz, M., di Tomaso, E., Zhu, A., Penson, R. T., Horowitz, N. S., Batchelor, T. T., Willett, C. G., & Jain, R. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.3544 · Cited by 8 · see citing works

Molecular mechanisms and clinical applications of angiogenesis

Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · see citing works

Basic and Therapeutic Aspects of Angiogenesis

Potente, M., Gerhardt, H., & Carmeliet, P. (2011) · Cell · doi:10.1016/j.cell.2011.08.039 · Cited by 2,771 · see citing works

Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges

Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027 · see citing works

Tumor angiogenesis: molecular pathways and therapeutic targets

Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,739 · see citing works

Normalization of the Vasculature for Treatment of Cancer and Other Diseases

Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605 · see citing works

Angiogenic signaling pathways and anti-angiogenic therapy for cancer

Liu, Z., Chen, H., Zheng, L., Sun, L., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,387 · see citing works

Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers

Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248 · see citing works

Ten years of anti-vascular endothelial growth factor therapy

Ferrara, N., & Adamis, A. P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.17 · Cited by 1,040 · see citing works

Strategies and challenges for the next generation of therapeutic antibodies

Beck, A., Wurch, T., Bailly, C., & Corvaı̈a, N. (2010) · Nature reviews. Immunology · doi:10.1038/nri2747 · Cited by 851 · see citing works

Senescence and cancer — role and therapeutic opportunities

Schmitt, C. A., Wang, B., & Demaria, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00668-4 · Cited by 794 · see citing works

Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions

Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 735 · see citing works

Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?

Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 674 · see citing works

Metronomic chemotherapy: new rationale for new directions

Pasquier, E., Kavallaris, M., & André, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.82 · Cited by 655 · see citing works

Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma

Keunen, O., Johansson, M., Oudin, A., Sanzey, M., Rahim, S. A. A., Fack, F., Thorsen, F. A., Taxt, T., Bartoš, M., Jiřík, R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1014480108 · Cited by 605 · see citing works

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

Rini, B. I., Cohen, D. P., Lu, D. R., Chen, I., Hariharan, S., Gore, M. E., Figlin, R. A., Baum, M. S., & Motzer, R. J. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djr128 · Cited by 580 · see citing works

HCC and angiogenesis: possible targets and future directions

Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.30 · Cited by 565 · see citing works

Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma

da Cruz, L. C. H., Rodríguez, I., Domingues, R. C., Gasparetto, E. L., & Sorensen, A. G. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2397 · Cited by 551 · see citing works

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

Batchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520 · see citing works

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

Frentzas, S., Simoneau, È., Bridgeman, V. L., Vermeulen, P., Foo, S., Kostaras, E., Nathan, M. R., Wotherspoon, A. C., Gao, Z., Shi, Y., et al. (2016) · Nature Medicine · doi:10.1038/nm.4197 · Cited by 456 · see citing works

Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors

Maitland, M. L., Bakris, G. L., Black, H. R., Chen, H. X., Durand, J., Elliott, W. J., Ivy, S. P., Leier, C. V., Lindenfeld, J. M., Liu, G., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq091 · Cited by 410 · see citing works

CXCL12 (SDF1α)-CXCR4/CXCR7 Pathway Inhibition: An Emerging Sensitizer for Anticancer Therapies?

Duda, D. G., Kozin, S. V., Kirkpatrick, N. D., Xu, L., Fukumura, D., & Jain, R. K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2636 · Cited by 397 · see citing works

A “Vascular Normalization Index” as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients

Sorensen, A. G., Batchelor, T. T., Zhang, W., Chen, P.-J., Yeo, P., Wang, M., Jennings, D. L., Wen, P. Y., Lahdenranta, J., Ancukiewicz, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0814 · Cited by 395 · see citing works

Targeting angiogenesis: progress with anti-VEGF treatment with large molecules

Grothey, A., & Galanis, E. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.110 · Cited by 356 · see citing works

Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease.

Goel, S., Wong, A. H.-K., & Jain, R. K. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006486 · Cited by 352 · see citing works

An overview of small-molecule inhibitors of VEGFR signaling

Ivy, S. P., Wick, J. Y., & Kaufman, B. M. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.130 · Cited by 350 · see citing works

Anti-angiogenesis therapy in cancer: Current challenges and future perspectives

Shojaei, F. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.008 · Cited by 348 · see citing works

Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation

Batchelor, T. T., Gerstner, E. R., Emblem, K. E., Duda, D. G., Kalpathy–Cramer, J., Snuderl, M., Ancukiewicz, M., Polaskova, P., Pinho, M. C., Jennings, D. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318022110 · Cited by 343 · see citing works

Perfusion and vascular permeability: Basic concepts and measurement in DCE-CT and DCE-MRI

Cuénod, C. A., & Balvay, D. (2013) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2013.10.010 · Cited by 310 · see citing works

Cancer imaging by optical coherence tomography: preclinical progress and clinical potential

Vakoc, B. J., Fukumura, D., Jain, R. K., & Bouma, B. E. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3235 · Cited by 299 · see citing works

Motion model ultrasound localization microscopy for preclinical and clinical multiparametric tumor characterization

Opacic, T., Dencks, S., Theek, B., Piepenbrock, M., Ackermann, D., Rix, A., Lammers, T., Stickeler, E., Delorme, S., Schmitz, G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03973-8 · Cited by 298 · see citing works

Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis

Lieu, C., Heymach, J., Overman, M., Tran, H., & Kopetz, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0659 · Cited by 286 · see citing works

Controlling escape from angiogenesis inhibitors

Sennino, B., & McDonald, D. M. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3366 · Cited by 265 · see citing works

Mechanisms of Resistance to Anti-Angiogenic Therapy and Development of Third-Generation Anti-Angiogenic Drug Candidates

Loges, S., Schmidt, T., & Carmeliet, P. (2010) · Genes & Cancer · doi:10.1177/1947601909356574 · Cited by 257 · see citing works

Interleukin-6 Stimulates Defective Angiogenesis

Gopinathan, G., Milagre, C., Pearce, O. M. T., Reynolds, L. E., Hodivala-Dilke, K., Leinster, D. A., Zhong, H., Hollingsworth, R. E., Thompson, R., Whiteford, J. R., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1227 · Cited by 249 · see citing works

PlGF: A Multitasking Cytokine with Disease-Restricted ActivityPreprint

Dewerchin, M. A., & Carmeliet, P. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011056 · Cited by 244 · see citing works

Anti-VEGF therapies in the clinic

Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237 · see citing works

Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics

Abdalla, A. M. E., Xiao, L., Ullah, M. W., Yu, M., Ouyang, C., & Yang, G. (2018) · Theranostics · doi:10.7150/thno.21674 · Cited by 240 · see citing works

Metastatic Colorectal Cancer: From Improved Survival to Potential Cure

Gallagher, D. J., & Kemeny, N. E. (2010) · Oncology · doi:10.1159/000315730 · Cited by 237 · see citing works

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

Sathornsumetee, S., Desjardins, A., Vredenburgh, J. J., McLendon, R. E., Marcello, J. E., Herndon, J. E., Mathe, A., Hamilton, M., Rich, J. N., Norfleet, J. A., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq099 · Cited by 230 · see citing works

Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2

Incio, J., Ligibel, J. A., McManus, D. T., Suboj, P., Jung, K., Kawaguchi, K., Pinter, M., Babykutty, S., Chin, S. M., Vardam, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0945 · Cited by 222 · see citing works

Forty-Year Journey of Angiogenesis Translational Research

Cao, Y., Arbiser, J. L., D’Amato, R. J., D'Amore, P. A., Ingber, D. E., Kerbel, R. S., Klagsbrun, M., Lim, S., Moses, M. A., Zetter, B. R., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003149 · Cited by 223 · see citing works

Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment

López de Andrés, J., Griñán-Lisón, C., Jiménez, G., & Marchal, J. A. (2020) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-020-00966-3 · Cited by 207 · see citing works

Cancer combination therapies by angiogenesis inhibitors; a comprehensive review

Ansari, M. J., Bokov, D., Markov, A., Jalil, A. T., Shalaby, M. N., Suksatan, W., Chupradit, S., AL-Ghamdi, H. S., Shomali, N., Zamani, A., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00838-y · Cited by 197 · see citing works

Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy

Gacche, R. N., & Meshram, R. J. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.05.002 · Cited by 195 · see citing works

International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1

Scagliotti, G. V., Vynnychenko, I. O., Park, K., Ichinose, Y., Kubota, K., Blackhall, F. H., Pirker, R., Galiulin, R., Ciuleanu, T., Sydorenko, O., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4987 · Cited by 184 · see citing works

Lessons From Anti–Vascular Endothelial Growth Factor and Anti–Vascular Endothelial Growth Factor Receptor Trials in Patients With Glioblastoma

Lu-Emerson, C., Duda, D. G., Emblem, K. E., Taylor, J. W., Gerstner, E. R., Loeffler, J. S., Batchelor, T. T., & Jain, R. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9575 · Cited by 179 · see citing works

The VEGF family in cancer and antibody-based strategies for their inhibition

Sullivan, L. A., & Brekken, R. A. (2010) · mAbs · doi:10.4161/mabs.2.2.11360 · Cited by 182 · see citing works

Scaling rules for diffusive drug delivery in tumor and normal tissues

Baish, J. W., Stylianopoulos, T., Lanning, R. M., Kamoun, W. S., Fukumura, D., Munn, L. L., & Jain, R. K. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018154108 · Cited by 182 · see citing works

Diastolic Blood Pressure as a Biomarker of Axitinib Efficacy in Solid Tumors

Rini, B. I., Schiller, J. H., Fruehauf, J. P., Cohen, E. E. W., Tarazi, J., Rosbrook, B., Bair, A. H., Ricart, A. D., Olszanski, A. J., Letrent, K. J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2806 · Cited by 181 · see citing works

Mechanisms of resistance to antiangiogenesis therapy

Azam, F., Mehta, S., & Harris, A. L. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.020 · Cited by 179 · see citing works

CT Perfusion in Oncologic Imaging: A Useful Tool?

García‐Figueiras, R., Goh, V., Padhani, A. R., Baleato‐González, S., Garrido, M., León‐Mateos, L., & Gómez‐Caamaño, A. (2012) · American Journal of Roentgenology · doi:10.2214/ajr.11.8476 · Cited by 175 · see citing works

Phase I Dose-Escalation Study and Biomarker Analysis of E7080 in Patients with Advanced Solid Tumors

Yamada, K., Yamamoto, N., Yamada, Y., Nokihara, H., Fujiwara, Y., Hirata, T., Koizumi, F., Nishio, K., Koyama, N., & Tamura, T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2638 · Cited by 162 · see citing works

Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1α, CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer

Xu, L., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Chung, D. C., Lauwers, G. Y., Samuel, R., Shellito, P. C., Czito, B. G., Lin, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2099 · Cited by 161 · see citing works

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

Zhu, A. X., Finn, R. S., Mulcahy, M. F., Gurtler, J., Sun, W., Schwartz, J. D., Dalal, R. P., Joshi, A., Hozak, R. R., Xu, Y., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1442 · Cited by 159 · see citing works

Intertwined regulation of angiogenesis and immunity by myeloid cells

Rivera, L. B., & Bergers, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.005 · Cited by 158 · see citing works

Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging

O’Connor, J. P. B., Carano, R. A. D., Clamp, A. R., Ross, J., Ho, C., Jackson, A., Parker, G. J. M., Rose, C. J., Peale, F. V., Jr., Friesenhahn, M. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0731 · Cited by 157 · see citing works

Pathological neoangiogenesis depends on oxidative stress regulation by ATM

Okuno, Y., Nakamura-Ishizu, A., Otsu, K., Suda, T., & Kubota, Y. (2012) · Nature Medicine · doi:10.1038/nm.2846 · Cited by 152 · see citing works

Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade

Li, Q., Wang, Y., Jia, W., Deng, H., Li, G., Deng, W., Chen, J., Kim, B. Y. S., Jiang, W., Liu, Q., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2179 · Cited by 153 · see citing works

Bevacizumab-induced hypertension: Clinical presentation and molecular understanding

Li, M., & Kroetz, D. L. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.012 · Cited by 152 · see citing works

VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016)

Peng, F.-W., Liu, D., Zhang, Q., Xu, Y., & Shi, L. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1344215 · Cited by 151 · see citing works

Liquid biopsy and therapeutic response: Circulating tumor cell cultures for evaluation of anticancer treatment

Khoo, B. L., Grenci, G., Jing, T., Lim, Y. B., Lee, S. C., Thiery, J. P., Han, J., & Lim, C. T. (2016) · Science Advances · doi:10.1126/sciadv.1600274 · Cited by 147 · see citing works

Inflammation-Based Prognostic Indices in Malignant Pleural Mesothelioma

Pinato, D. J., Mauri, F. A., Ramakrishnan, R., Wahab, L., Lloyd, T., & Sharma, R. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823f45c1 · Cited by 147 · see citing works

Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2–Associated Vestibular Schwannomas

Blakeley, J. O., Ye, X., Duda, D. G., Halpin, C. F., Bergner, A. L., Muzikansky, A., Merker, V. L., Gerstner, E. R., Fayad, L. M., Ahlawat, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.3817 · Cited by 143 · see citing works

Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma

Lu, K. V., & Bergers, G. (2012) · CNS Oncology · doi:10.2217/cns.12.36 · Cited by 139 · see citing works

Effects of Anti-VEGF Treatment Duration on Tumor Growth, Tumor Regrowth, and Treatment Efficacy

Bagri, A., Berry, L., Gunter, B., Singh, M., Kasman, I. M., Damico, L. A., Xiang, H., Schmidt, M., Fuh, G., Hollister, B. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3100 · Cited by 140 · see citing works

Photodynamic Therapy Synergizes with Irinotecan to Overcome Compensatory Mechanisms and Improve Treatment Outcomes in Pancreatic Cancer

Huang, H., Mallidi, S., Liu, J., Chiang, C.-T., Mai, Z., Goldschmidt, R., Ebrahim-Zadeh, N., Rizvi, I., & Hasan, T. G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0391 · Cited by 139 · see citing works

Redundant angiogenic signaling and tumor drug resistance

Gacche, R. N., & Assaraf, Y. G. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.01.002 · Cited by 139 · see citing works

Angiopoietin-2 Interferes with Anti-VEGFR2–Induced Vessel Normalization and Survival Benefit in Mice Bearing Gliomas

Chae, S.-S., Kamoun, W. S., Farrar, C. T., Kirkpatrick, N. D., Niemeyer, E., de Graaf, A. M. A., Sorensen, A. G., Munn, L. L., Jain, R. K., & Fukumura, D. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3073 · Cited by 135 · see citing works

The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study

Lewin, M., Fartoux, L., Vignaud, A., Arrivé, L., Menu, Y., & Rosmorduc, O. (2010) · European Radiology · doi:10.1007/s00330-010-1914-4 · Cited by 137 · see citing works

Effective Suppression of Vascular Network Formation by Combination of Antibodies Blocking VEGFR Ligand Binding and Receptor Dimerization

Tvorogov, D., Anisimov, A., Zheng, W., Leppänen, V., Tammela, T., Laurinavičius, S., Holnthoner, W., Heloterä, H., Holopainen, T., Jeltsch, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.11.001 · Cited by 135 · see citing works

Towards novel paradigms for cancer therapy

Pavet, V., Portal, M. M., Moulin, J.-F., Herbrecht, R., & Gronemeyer, H. (2010) · Oncogene · doi:10.1038/onc.2010.460 · Cited by 132 · see citing works

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

Joaquim Bellmunt, B., González-Larriba, J. L., Prior, C., Maroto, P., Carles, J., Castellano, D., Mellado, B., Gallardo, E., Perez‐Gracia, J. L., Aguilar, G., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr023 · Cited by 127 · see citing works

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer

Heist, R. S., Duda, D. G., Sahani, D. V., Ancukiewicz, M., Fidias, P., Sequist, L. V., Temel, J. S., Shaw, A. T., Pennell, N. A., Neal, J. W., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424024112 · Cited by 126 · see citing works

Phase II Study of Bevacizumab in Patients With HIV-Associated Kaposi's Sarcoma Receiving Antiretroviral Therapy

Uldrick, T. S., Wyvill, K. M., Kumar, P. P., O’Mahony, D., Bernstein, W., Aleman, K. O., Polizzotto, M. N., Steinberg, S. M., Pittaluga, S., Marshall, V. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6853 · Cited by 124 · see citing works

Quantifying Tumor Vascular Heterogeneity with Dynamic Contrast‐Enhanced Magnetic Resonance Imaging: A Review

Yang, X., & Knopp, M. V. (2011) · BioMed Research International · doi:10.1155/2011/732848 · Cited by 123 · see citing works

Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma

Tomita, Y., Uemura, H., Fujimoto, H., Kanayama, H., Shinohara, N., Nakazawa, H., Imai, K., Umeyama, Y., Ozono, S., Naito, S., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.07.014 · Cited by 123 · see citing works

Glasgow Prognostic Score is a Predictor of Perioperative and Long-term Outcome in Patients with only Surgically Treated Esophageal Cancer

Vashist, Y. K., Loos, J., Dedow, J., Tachezy, M., Uzunoglu, G., Kutup, A., Yekebas, E. F., & Izbicki, J. R. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1383-7 · Cited by 121 · see citing works

Anti–Vascular Endothelial Growth Factor Therapies as a Novel Therapeutic Approach to Treating Neurofibromatosis-Related Tumors

Wong, H. K., Lahdenranta, J., Kamoun, W. S., Chan, A. W., McClatchey, A. I., Plotkin, S. R., Jain, R. K., & di Tomaso, E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3107 · Cited by 121 · see citing works

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients

Tolaney, S. M., Ziehr, D. R., Guo, H., Ng, M. R., Barry, W. T., Higgins, M. J., Isakoff, S. J., Brock, J. E., Ivanova, E. V., Paweletz, C. P., et al. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0229 · Cited by 118 · see citing works

Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma

Nowosielski, M., Wiestler, B., Goebel, G., Hutterer, M., Schlemmer, H. P., Stockhammer, G., Wick, W., Bendszus, M., & Radbruch, A. (2014) · Neurology · doi:10.1212/wnl.0000000000000402 · Cited by 115 · see citing works

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients

Lee, E. Q., Kaley, T. J., Duda, D. G., Schiff, D., Lassman, A. B., Wong, E. T., Mikkelsen, T., Purow, B. W., Muzikansky, A., Ancukiewicz, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3220 · Cited by 114 · see citing works

Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs

on behalf of the Bioanalysis and Quality Assurance (BAQA) Group of the ECMC, Cummings, J., Raynaud, F. I., Jones, J. L., Sugar, R., & Dive, C. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605910 · Cited by 112 · see citing works

AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: A randomized, double‐blind, placebo‐controlled, phase 2 study

Rini, B., Szczylik, C., Tannir, N. M., Koralewski, P., Tomczak, P., Deptala, A., Dirix, L. Y., Fishman, M., Ramlau, R., Ravaud, A., et al. (2012) · Cancer · doi:10.1002/cncr.27632 · Cited by 110 · see citing works

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

Rodon, J. A., Carducci, M. A., Sepúlveda-Sánchez, J. M., Azaro, A., Calvo, E., Seoane, J., Braña, I., Sicart, E., Gueorguieva, I., Cleverly, A., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0192-4 · Cited by 108 · see citing works

Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients

Ronzoni, M., Manzoni, M., Mariucci, S., Loupakis, F., Brugnatelli, S., Bencardino, K. B., Rovati, B., Tinelli, C., Falcone, A., Villa, E., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq261 · Cited by 108 · see citing works

The VEGF pathway in lung cancer

Alevizakos, M., Kaltsas, S., & Syrigos, K. N. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2298-3 · Cited by 106 · see citing works

Controlling angiogenesis in breast cancer: A systematic review of anti-angiogenic trials

Mackey, J. R., Kerbel, R. S., Gelmon, K. A., McLeod, D., Chia, S., Rayson, D., Verma, S., Collins, L. L., Paterson, A. H. G., Robidoux, A., et al. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.12.002 · Cited by 105 · see citing works

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma

Ceresoli, G. L., Zucali, P. A., Mencoboni, M., Botta, M., Grossi, F., Cortinovis, D. L., Zilembo, N., Ripa, C., Tiseo, M., Favaretto, A. G., et al. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.368 · Cited by 105 · see citing works

Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis

Sareen, H., Ma, Y., Becker, T. M., Roberts, T. L., SOUZA, P. D., & Powter, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168835 · Cited by 104 · see citing works

Hypertension During Vascular Endothelial Growth Factor Inhibition: Focus on Nitric Oxide, Endothelin-1, and Oxidative Stress

Lankhorst, S., Kappers, M. H. W., van Esch, J. H. M., Danser, A. H. J., & van den Meiracker, A. H. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5244 · Cited by 99 · see citing works

The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer

Ribatti, D., Solimando, A. G., & Pezzella, F. (2021) · Cancers · doi:10.3390/cancers13143433 · Cited by 99 · see citing works

Population pharmacokinetic–pharmacodynamic modelling in oncology: a tool for predicting clinical response

Bender, B. C., Schindler, E., & Friberg, L. E. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12258 · Cited by 99 · see citing works

Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma

Grivas, P. D., Daignault, S. D., Tagawa, S. T., Nanus, D. M., Stadler, W. M., Dreicer, R., Kohli, M., Petrylak, D. P., Vaughn, D. J., Bylow, K. A., et al. (2013) · Cancer · doi:10.1002/cncr.28477 · Cited by 98 · see citing works

Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors

Hosaka, K., Yang, Y., Seki, T., Du, Q., Xu, J., He, X., Wu, J., Zhang, Y., Morikawa, H., Nakamura, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17525-6 · Cited by 98 · see citing works

Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patients

Donskov, F. N., Michaelson, M. D., Puzanov, I. J., Davis, M. P., Bjarnason, G. A., Motzer, R. J., Goldstein, D., Lin, X., Cohen, D. P., Wiltshire, R., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.368 · Cited by 97 · see citing works

Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies

Comunanza, V., & Bussolino, F. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00101 · Cited by 95 · see citing works

Plasma Soluble VEGFR-1 Is a Potential Dual Biomarker of Response and Toxicity for Bevacizumab with Chemoradiation in Locally Advanced Rectal Cancer

Duda, D. G., Willett, C. G., Ancukiewicz, M., di Tomaso, E., Shah, M., Czito, B. G., Bentley, R. C., Poleski, M. H., Lauwers, G. Y., Carroll, M. D., et al. (2010) · The Oncologist · doi:10.1634/theoncologist.2010-0029 · Cited by 95 · see citing works

The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer

Missiaen, R., Mazzone, M., & Bergers, G. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.002 · Cited by 94 · see citing works

Angiogenesis in Neuroendocrine Tumors: Therapeutic Applications

Scoazec, J. (2012) · Neuroendocrinology · doi:10.1159/000338371 · Cited by 95 · see citing works

Anti-VEGF Treatment–Resistant Pancreatic Cancers Secrete Proinflammatory Factors That Contribute to Malignant Progression by Inducing an EMT Cell Phenotype

Carbone, C., Moccia, T., Zhu, C., Paradiso, G., Budillon, A., Chiao, P. J., Abbruzzese, J. L., & Melisi, D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1185 · Cited by 92 · see citing works

Biomarkers of Response and Resistance to Anti-angiogenic Treatment

Duda, D. G. (2013) · Springer eBooks · doi:10.1007/978-94-007-6467-5_15

Abstract IA08: Biomarkers of response and resistance to anti-angiogenic therapy

Duda, D. G. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1538-8514.tumang15-ia08

[Biomarkers of antiangiogenic therapy].

Bai, C. (2010) · PubMed · doi:10.3881/j.issn.1000-503x.2010.04.001

Biomarkers predicting tumor response and evasion to anti-angiogenic therapy

Jahangiri, A., & Aghi, M. K. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.10.004 · Cited by 23 · see citing works

Biomarkers of Antiangiogenic Therapy: How Do We Move From Candidate Biomarkers to Valid Biomarkers?

Duda, D. G., Ancukiewicz, M., & Jain, R. K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8021 · Cited by 51 · see citing works